Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease (M-HEMORRH'AGE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04282486|
Recruitment Status : Not yet recruiting
First Posted : February 24, 2020
Last Update Posted : February 25, 2020
The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g "Franchini & Mannuccio", BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated.
Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.
|Condition or disease||Intervention/treatment|
|Hemophilia||Other: Telephone interview|
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Medication Exposure in Older Patients (AGEd > 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease).|
|Estimated Study Start Date :||April 2020|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2020|
- Other: Telephone interview
Primary objective: potentially inappropriate medication prevalence
Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index
A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.
- Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list. [ Time Frame: At inclusion ]A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04282486
|Contact: Teddy NOVAIS, MD||4 72 43 21 55 ext +email@example.com|
|Contact: Valérie CHAMOUARDfirstname.lastname@example.org|